Kornimate/medical-research-clean huggingface dataset:
high-fiber diet on the body and the brain

Conditions: Diet Modification; Overweight

Summary: the central research question aims to understand what drives individuals to make and maintain a vegan / vegetarian dietary decision, to investigate whether there are possible predictors that might influence such a decision and whether personality differences already exist or can only be measured after the change in diet. the investigators will examine the effects of a high-fiber diet on food wanting on a neural and on a behavioral level. the microbiome is suggested to mediate the expected changes in food wanting.


Eligibility criteria:
inclusion criteria: * body-mass-index 25-30kg/m\^2 * females on contraception only exclusion criteria: * current neurological or psychiatric illness * daily consumption of more than 50 g of alcohol, more than 10 cigarettes or more than 6 cups of coffee * use of antidepressants or other centrally acting drugs * type 2 diabetes mellitus or other serious metabolic disorders * mri contraindication (e.g. cardiac pacemaker, drug pump, shunts) * major untreated medical condition, including gastrointestinal organs, lungs, heart, cardiovascular system, liver and kidney) * diet-related restrictions (food allergies, food intolerances, known nutrient deficiencies or a recent history of dieting or restrictive eating behaviour, including vegan, vegetarian diet) * current pregnancy or lactation

Keywords: microbiome food wanting memory fiber
validation of saliva in the esoterix genetic laboratories fragile x assay

Conditions: Fragile X Syndrome

Summary: the purpose of this research is to determine if saliva samples can be used as an alternate sample type to test for fragile x. by using saliva instead of blood, it would be easier for patients to have fragile x testing.

saliva samples will be prospectively collected from subjects who have previously been tested by esoterix genetic laboratories, llc using blood specimens and diagnosed as fragile x intermediates, premutations (carriers) or full mutations (affected). results from fragile x testing with saliva will be compared to results from the blood sample that was previously submitted to esoterix genetic laboratories for testing. data from this study will be used for regulatory submissions.

Eligibility criteria:
inclusion criteria: * subject has previously been identified through molecular testing at esoterix genetic laboratories as a fragile x intermediate, premutation (carrier) or full mutation (affected). * in the opinion of the subject's physician, the subject is medically stable and able to provide the required quantity of saliva. * if subject is at least 18 years of age: * subject must be willing to give written informed consent * subject must be willing to comply with the collection procedure * if subject is under 18 years of age, the legally authorized representative must give written informed consent and agree to comply with study procedures. exclusion criteria: * subject has been determined to be an individual with a normal fmr1 gene. * subject has a known medical condition that would cause risk to the donor or, if relevant, the fetus as a result of saliva collection.

Keywords: fragile x syndrome fragile x full mutation fragile x premutation fragile x intermediate cgg repeat length
improving fecal occult blood test completion rates among veterans

Conditions: Colorectal Cancer

Summary: this is a 4-arm cluster randomized controlled trial to evaluate whether patient financial incentives directly integrated into primary care can improve fecal occult blood test (fobt) completion rates. we will recruit primary care patients at the philadelphia veterans affairs medical center (pvamc) in 2 stages. in stage 1, we hypothesize that, compared to usual care, $5, $10, $20 incentives will each lead to a statistically significant increase in the rate of fobt completion. we also hypothesize that there will be a direct dose-response relationship between the incentive amount and rates of fobt completion. in stage 2, we hypothesize that a lottery-based incentive and a raffle-based incentive will both lead to a statistically significant increase in the rate of fobt completion compared to a fixed payment incentive with an equivalent dollar per patient value.


Eligibility criteria:
inclusion criteria: * pvamc outpatients who are prescribed an fobt kit in module b or c during the study period. exclusion criteria: * none. all pvamc outpatients who are prescribed an fobt kit in module b or c during the study period will be eligible.

Keywords: screening colon cancer incentives behavioral economics
qigong for ppsp in breast cancer pain in breast cancer survivors

Conditions: Breast Cancer Surgery Pain; Breast Cancer; Stage 0-III Breast Cancer

Summary: studies have shown that on-going pain following breast surgery is common and may limit the ability to participate in physical activity, cause tiredness, difficulty in daily chores/activities as well as other problems. this study is evaluating whether participating in a 12-week qigong program (pronounced chee kung), an exercise program that involves gentle movements combined with breathing/relaxation techniques, also known as mind-body exercise, leads to improvement of pain, physical function, and quality of life among breast cancer survivors that have significant pain following surgery.

this is a pilot/feasibility study designed to look at the potential benefits of a 12-week program of qigong mind-body exercise program. the study applies to women who have completed physical therapy treatment on symptoms such as pain, and difficulty moving/strength of arm in women who are experiencing on-going symptoms after breast cancer surgery. the results of this study will be used to help design future studies of the effect of qigong programs in breast cancer survivors.

Eligibility criteria:
inclusion criteria: * history of stage 0-iii breast cancer; * persistent post-surgical pain at least 3 months after completion of surgery, chemotherapy, and/or radiation; * completion of a course of physical therapy exclusion criteria: * unstable cardiovascular disease in the last 6 months * psychiatric disorders or conditions that would preclude participation in the study intervention (e.g. untreated major depression or psychosis, substance abuse, severe personality disorder); * metastatic breast or other cancer; * participation in more than 240 minutes of moderate-intensity exercise per week (as determined by leisure score index questionnaire) * pregnant or breastfeeding * recent history of attending regular qmbe or similar classes (e.g. yoga or tai chi classes), (i.e.20 or more classes in the past 6 months). * currently enrolled in a physical therapy course

Keywords: breast cancer surgery pain breast cancer
assessment of cerebral blood flow asymmetry in cardiac surgery patients undergoing hypothermic circulatory arrest

Conditions: Cerebral Desaturation; Cerebral Ischemia

Summary: cerebral oxygen desaturation during cardiac surgery measured using near infrared spectroscopy (nirs) derived cerebral oximetry has been associated with significant postoperative morbidity. if significant desaturation occurs during this period, it may represent an ideal opportunity to further optimize the postoperative care of these patients.

selective antegrade cerebral perfusion (sacp) is a commonly used technique for maintaining cerebral blood flow (cbf) during the use of hypothermic cardiac arrest (hca) for aortic arch reconstruction. however, even with an intact circle of willis, asymmetric cbf is a common occurrence during hca when sacp is used. the investigators have previously shown that ultrasound guided extrinsic compression of the left carotid artery can increase left cerebral oxygen saturation, and improved symmetry of cbf; however, this has not been investigated formally. in this study, the investigators will firstly formally assess the incidence and severity of asymmetrical cerebral flow between the left and right hemispheres in patients undergoing aortic arch repair (n=20). cbf will be assessed indirectly through regional cerebral oxygen saturation (rso2) measured via near-infrared spectroscopy-derived cerebral oximetry. in addition, a number of clinical outcome parameters (up to 30 days post-op) will be evaluated. the investigators expect that significant left-side cerebral hypoperfusion will consistently be observed in patients undergoing aortic arch repair using sacp.

Eligibility criteria:
inclusion criteria: * informed consent * age 18 years or older * surgery requiring cardio pulmonary bypass * ascending aorta or arch repair surgery * surgery requiring hypothermic circulatory arrest exclusion criteria: * off-pump cardiac surgery * skin condition preventing the use of cerebral oximetry pads

Keywords: near-infrared spectroscopy-derived cerebral oximetry
imrt and primary transoral surgery in the treatment of squamous cell carcinomas

Conditions: Squamous Cell Carcinoma

Summary: compare patients' feelings in terms of swallowing ability assessed by the overall score of md anderson dysphagia inventory (mdadi) 2 years after starting treatment between patients who have been treated with imrt and those who were treated by transoral surgery for a squamous cell carcinoma of the early stage oropharynx.


Eligibility criteria:
inclusion criteria: 1. age ≥ 18 years old 2. ecog performance status 0-2 3. histologically confirmed squamous cell carcinoma 4. primitive localization of the oropharynx on the tonsil compartment or the tongue base 5. p16 or hpv status available 6. tnm classification ajcc7th t1 or t2 7. tnm classification ajcc7th n0 or n1 8. patient and tumor that can be treated by radiotherapy or by transoral surgery 9. patient who has not objected to participate after being informed about the study. the patient must be able and willing to cooperate in follow-up and study visits exclusion criteria: 1. severe medical comorbidity or other contraindication to radiotherapy or surgery 2. primary tumor or unresectable lymphadenopathy 3. metastatic disease 4. history of squamous cell carcinoma of the head and neck within 5 years 5. history of radiation therapy to the head and neck 6. inability to undergo or complete radiation therapy follow-up consultations 7. history of cancer except free of any disease for at least 5 years, with the exception of non-melanoma skin cancers 8. inability to complete questionnaires 9. pregnant or lactating woman 10. patient under tutorship or curatorship, deprived of liberty or unable to do so to express consent
sensory-cognitive and physical fitness training in mild cognitive impairment

Conditions: Mild Cognitive Impairment (MCI); Mild Alzheimer's Disease

Summary: age-related cognitive decline is unavoidable. however, recent results of neuroplasticity-based research show that neuroplasticity-based training and physical activity might have the potential to decelerate or even reverse effects of aging and age-related cognitive impairments. little is known whether these results also apply to pathological processes of aging such as mild cognitive impairment (mci) and dementia. this multi-center study aims at investigating efficiency and feasibility of a neuroplasticity-based auditory discrimination training and a physical fitness training for patients suffering from mild cognitive impairment or mild alzheimer's disease (mini mental state examination, mmse \> 19). evaluation will include neuropsychological testing, electroencephalography (eeg) and magnetic resonance imaging (mri) measurements as well as blood and liquor analyses.


Eligibility criteria:
inclusion criteria: * focus: subjective and/or objective memory complaints with mmse \> 19 (mci or mild alzheimer's disease, with stable medication for at least 3 months) * mild to moderate depression * corrected-to-normal hearing and vision * for mri: non-magnetic metals inside the body * right handedness preferred exclusion criteria: * cognitive impairment/ dementia with mmse \< 20, severe psychiatric or neurological disease (current and lifetime) * physical health that does not allow physical fitness tests and trainings * benzodiazepin, tricyclic antidepressants * for mri: magnetic metal inside the body, cardiac pacemaker etc. * for liquor: insufficient blood coagulation, insufficient brain pressure

Keywords: neuroplasticity mild cognitive impairment (mci) alzheimer sensory-cognitive training physical fitness
serum markers in merkel cell carcinoma patients: a longitudinal monitoring study for optimization of european guidelines

Conditions: Merkel Cell Carcinoma

Summary: merkel cell carcinoma (mcc) is a rare aggressive skin carcinoma. approximately 80% of mcc are related to the merkel cell polyomavirus (mcpyv). although rates of relapse are high, the follow-up strategy lacks consensus. patients are usually assessed clinically every 3 to 6 months for the first 2-3 years, and every 6 to 12 months thereafter. in the european guidelines, patients with early stages are monitored with clinical examination and ultrasonography of lymph nodes, while whole-body imaging is optional in patients with stage iii disease, on a yearly basis for 5 years. such strategy may prevent the diagnosis of infra-clinical recurrences, whereas patients could still be treated with surgery or radiation therapy. until 2017, patients with advanced disease were treated with chemotherapies, with no long-term benefit. immunotherapies with pd-1/pd-l1 inhibitors currently allow durable responses in 50% of such patients. this major change in the management of mcc patients argues for a follow-up strategy that would allow early diagnosis of infra-clinical metastases, when tumoral burden is still low. given that all patients cannot be monitored by systematic regular imaging, additional non-invasive tools are needed. blood-based biomarkers as a surrogate of tumor burden are advantageous as they can be repeated over time, providing guidance on when imaging is necessary. the study aims to assess two blood biomarkers, mcpyv t-ag antibodies and cell-free mir-375, in a prospective fashion from baseline diagnosis, in a cohort of 150 european mcc patients


Eligibility criteria:
inclusion criteria: * patients with a " de novo " diagnosis of mcc, confirmed on histological criteria (neuroendocrine morphology, ck20 staining and/or neuroendocrine and/or satb2 staining, exclusion of differential diagnosis) * ≥ 18 years of age * written informed consent obtained from the participant exclusion criteria: * patients following any measures of legal presentation * pregnancy or breastfeeding

Keywords: biomarker monitoring prognosis merkel cell polyomavirus mir375 t-antigen antibodies
a study of roactemra/actemra (tocilizumab) with or without methotrexate in patients with mild to moderate rheumatoid arthritis with an inadequate response to methotrexate

Conditions: Rheumatoid Arthritis

Summary: this multicenter study with a randomized, double-blind, parallel-group phase will evaluate the safety and efficacy of roactemra/actemra (tocilizumab) in combination with methotrexate versus roactemra/actemra monotherapy in patients with mild to moderate rheumatoid arthritis, with an inadequate response to methotrexate. patients will receive roactemra/actemra 8 mg/kg intravenously every 4 weeks plus oral methotrexate 15-25 mg weekly for 12 weeks. patients with a good/moderate eular response will then be randomized to receive either roactemra/actemra plus methotrexate or roactemra/actemra plus placebo for the following 12 weeks. anticipated time on study treatment is 6 months.


Eligibility criteria:
inclusion criteria: * adult patients, \>/= 18 years of age * rheumatoid arthritis of \>/= 1 year duration * mild to moderate disease activity at screening (das 28 \ 2.6) * on methotrexate treatment for at least 12 weeks, at stable oral dose of (10)15 mg to 25 mg/week for at least 6 weeks prior to day 1 * body weight \</= 150 kg * oral corticosteroids must have been at stable dose (maximum 10 mg/day) for at least 25 out of 28 days prior to baseline exclusion criteria: * major surgery (including joint surgery) within 8 weeks prior to screening or planned major surgery within 6 months after baseline * rheumatic autoimmune disease other than rheumatoid arthritis * functional class iv american college of rheumatology (acr) classification * prior history of or current inflammatory joint disease other than rheumatoid arthritis * treatment with a biologic agent at any time prior to baseline * treatment with traditional dmards other than methotrexate within 1 month (for leflunomide 3 months) prior to baseline * intraarticular or parenteral corticosteroids within 6 weeks prior to baseline * previous treatment with tocilizumab * pregnant or lactating women * uncontrolled disease states, such as asthma, psoriasis or inflammatory bowel disease where flares are commonly treated with oral or parenteral corticosteroids * known active current or history of recurrent bacterial, viral, fungal, mycobacterial or other infections * history of or currently active primary or secondary immunodeficiency * evidence of active malignant disease, malignancies diagnosed within the previous 5 years * active tuberculosis requiring treatment within the previous 3 years * positive for hiv infection
appetite response to exercise- versus energy restriction-induced energy deficit in adolescents with obesity.

Conditions: Pediatric Obesity

Summary: the aim of the present study is to compare the effect of iso-energetic energy deficits induced by exercise or dietary restriction on energy intake and appetite feelings in adolescents with obesity

the present study will compare the nutritional response to an energy deficit of 400 kcal induced once by realisation of an acute exercise set at moderate intensity and once by a dietary restriction imposed at lunch (compared with a control condition). 18 adolescents with obesity will be asked to randomly complete three experimental sessions: i) one control session (con); ii) one session with an exercise-induced energy deficit (def-ex); iii) one session with an energy restriction-induced energy deficit (def-ei). their ad libitum energy intake will be assessed during dinner time. appetite feelings will be assessed at regular intervals and their food reward in response to the lunch will also be assessed.

Eligibility criteria:
inclusion criteria: * bmi percentile \> 97th percentile according to the french curves. * ages 12-16 years old * signed consent form * being registered in the national social security system * no contraindication to physical activity exclusion criteria: * previous surgical interventions that is considered as non-compatible with the study. * diabetes * weight loss during the last 6 months * cardiovascular disease or risks

Keywords: appetite control obesity adolescents exercise energy deficit
holter of movement in patients with multiple sclerosis in controlled environment.

Conditions: Multiple Sclerosis

Summary: actisep is a multicentric academic study. ambulant patients with multiple sclerosis may be included on a voluntary basis. we plan to include a group of approximately 20 patients with ms. this study include a unique evaluation in the laboratory of analysis of human movement. a set of tasks will be performed by patients wearing of two magneto-inertial sensors.


Eligibility criteria:
inclusion criteria: * confirmed ms diagnosis, * over 18 years old, * ambulant patients, * signed informed consent, * no clinical and / or radiological relapse within 3 months. exclusion criteria: * patients with excessive cognitive disorders, limiting the understanding of task or with apparent communication difficulties hindering data collection. * any other previous or present pathology having an impact on motor function. * recent surgery or trauma (less than 6 months) in the upper or lower limbs

Keywords: actimyo accelerometry motion laboratory
refractory urge incontinence and botox injections

Conditions: Urinary Incontinence; Detrusor Overactivity; Urinary Urgency; Urge Urinary Incontinence

Summary: the purpose of this study is to see whether botox a (injected into the bladder muscle) can improve symptoms of urge incontinence that has not improved with usual medical treatments.

women who suffer with urge incontinence may not get relief with usual medical treatment (such as medications or behavioral techniques). we plan to enroll women with refractory urge incontinence in centers across the us. study participants will undergo cystoscopy (telescope look into the bladder) and injection of either botox a or placebo. if symptoms are not adequately relieved, subjects participants will receive a second injection that is botox a. participants are interviewed monthly by study personnel to determine symptoms and health status.

Eligibility criteria:
inclusion criteria: * adult women * detrusor overactivity incontinence confirmed by urodynamic testing * symptoms refractory to standard first- and second-line treatments * 6 or more urge incontinence episodes on 3-day bladder diary * normal neurological examination exclusion criteria: * urinary retention * allergy to botox (botulinum toxin a) * previous bladder treatment with botox (botulinum toxin a) in the past year * pregnancy or planning pregnancy within next year * neurologic disease with impaired neurotransmission

Keywords: botulinum toxin a urinary incontinence detrusor overactivity
efficacy of emono as an add-on therapy to conventional antidepressants for the treatment of depressive symptoms in nursing-home residents with neurocognitive disorders: a randomized controlled trial-

Conditions: Depression; Neurocognitive Disorders

Summary: depression in neurocognitive disorders (alzheimers' disease and related disoders) is a highly prevalent condition, especially in nursing homes. while it is associated with significant distress, the current conventional antidepressants have shown only modest efficacy and exposed to potentially severe side effects. recent evidence suggests that nitrous oxide (n2o) in its most commonly used packaging of emono (equimolar mixture of oxygen and nitrous oxide) has rapid antidepressant properties and a good safety profile. however, no study has investigating the antidepressant effect of emono in a population of depressed older adults with moderate to severe neurocognitive disorders in nursing homes. the principal goal of the proto-ehpad study is to compare the changes in depressive symptoms in such individuals in a randomized controlled trial with a follow up period of 8 weeks, with a dosage escalation procedure.

participants will be exposed to 3 sessions of emono (or medical air), with intervals of 1 week between sessions : a first session of 20 minutes, a second of 40 minutes one week later and a final session of 60 minutes one week later. efficacy will be assessed 1 week after each session and 4 weeks after the last session.

Eligibility criteria:
inclusion criteria: * men and women aged 60 and over living in nursing home * diagnosis of major neurocognitive disorder according to dsm-v for at least 6 month * mmse \<= 20/30 * npi depression \>= 4/12 * patient, family and legal representive consent where applicable person affiliated to a social security schem exclusion criteria: * npi agitation \> 6/12 * unstable somatic pathology (in particular unstable neurological or cardiological pathologies at risk of interfering with the diffusion of meopa) and any unexplained recent neurological abnormality. * contraindications to the use of meopa * patients who have already been treated with meopa in the 6 months prior to inclusion, for example for painful treatment * sub-physiological plasma vitamin b12 or b9 concentration (below the lower limit of the laboratory value). * a person participating in a clinical drug study or in a period of exclusion from any clinical study due to previous participation * personne participant à une étude clinique médicamenteuse ou en période d'exclusion de toute étude clinique du fait d'une précédente participation

Keywords: nitrous oxide